214 related articles for article (PubMed ID: 20372803)
1. Metastases of squamous cell carcinoma of the head and neck show increased levels of nucleotide excision repair protein XPF in vivo that correlate with increased chemoresistance ex vivo.
Köberle B; Ditz C; Kausch I; Wollenberg B; Ferris RL; Albers AE
Int J Oncol; 2010 May; 36(5):1277-84. PubMed ID: 20372803
[TBL] [Abstract][Full Text] [Related]
2. Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer.
Hsu DS; Lan HY; Huang CH; Tai SK; Chang SY; Tsai TL; Chang CC; Tzeng CH; Wu KJ; Kao JY; Yang MH
Clin Cancer Res; 2010 Sep; 16(18):4561-71. PubMed ID: 20823140
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression.
Usanova S; Piée-Staffa A; Sied U; Thomale J; Schneider A; Kaina B; Köberle B
Mol Cancer; 2010 Sep; 9():248. PubMed ID: 20846399
[TBL] [Abstract][Full Text] [Related]
4. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
[TBL] [Abstract][Full Text] [Related]
5. ERCC1 and XPF expression in human testicular germ cell tumors.
Köberle B; Brenner W; Albers A; Usanova S; Thüroff JW; Kaina B
Oncol Rep; 2010 Jan; 23(1):223-7. PubMed ID: 19956886
[TBL] [Abstract][Full Text] [Related]
6. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours.
Cierna Z; Miskovska V; Roska J; Jurkovicova D; Pulzova LB; Sestakova Z; Hurbanova L; Machalekova K; Chovanec M; Rejlekova K; Svetlovska D; Kalavska K; Kajo K; Babal P; Mardiak J; Ward TA; Mego M; Chovanec M
BMC Cancer; 2020 Jan; 20(1):17. PubMed ID: 31906898
[TBL] [Abstract][Full Text] [Related]
7. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
[TBL] [Abstract][Full Text] [Related]
8. ERCC1, XPF and XPA-locoregional differences and prognostic value of DNA repair protein expression in patients with head and neck squamous cell carcinoma.
Prochnow S; Wilczak W; Bosch V; Clauditz TS; Muenscher A
Clin Oral Investig; 2019 Aug; 23(8):3319-3329. PubMed ID: 30498981
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma.
Zuo N; Ma L; Liu T; Hu W; Luo Y; Meng H; Ren Q; Deng Y; Wei L; Liu Q
Oral Oncol; 2023 May; 140():106367. PubMed ID: 36996606
[TBL] [Abstract][Full Text] [Related]
10. Regulation of DNA repair gene expression in human cancer cell lines.
McGurk CJ; Cummings M; Köberle B; Hartley JA; Oliver RT; Masters JR
J Cell Biochem; 2006 Apr; 97(5):1121-36. PubMed ID: 16315315
[TBL] [Abstract][Full Text] [Related]
11. DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients.
Schena M; Guarrera S; Buffoni L; Salvadori A; Voglino F; Allione A; Pecorari G; Ruffini E; Garzino-Demo P; Bustreo S; Consito L; Bironzo P; Matullo G
DNA Repair (Amst); 2012 Apr; 11(4):374-80. PubMed ID: 22284908
[TBL] [Abstract][Full Text] [Related]
12. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines.
Welsh C; Day R; McGurk C; Masters JR; Wood RD; Köberle B
Int J Cancer; 2004 Jun; 110(3):352-61. PubMed ID: 15095299
[TBL] [Abstract][Full Text] [Related]
13. High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area.
Chiu TJ; Chen CH; Chien CY; Li SH; Tsai HT; Chen YJ
J Transl Med; 2011 Mar; 9():31. PubMed ID: 21426588
[TBL] [Abstract][Full Text] [Related]
14. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
Bauman JE; Austin MC; Schmidt R; Kurland BF; Vaezi A; Hayes DN; Mendez E; Parvathaneni U; Chai X; Sampath S; Martins RG
Br J Cancer; 2013 Oct; 109(8):2096-105. PubMed ID: 24064970
[TBL] [Abstract][Full Text] [Related]
15. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours.
Köberle B; Masters JR; Hartley JA; Wood RD
Curr Biol; 1999 Mar; 9(5):273-6. PubMed ID: 10074455
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.
McNeil EM; Astell KR; Ritchie AM; Shave S; Houston DR; Bakrania P; Jones HM; Khurana P; Wallace C; Chapman T; Wear MA; Walkinshaw MD; Saxty B; Melton DW
DNA Repair (Amst); 2015 Jul; 31():19-28. PubMed ID: 25956741
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
Arora S; Kothandapani A; Tillison K; Kalman-Maltese V; Patrick SM
DNA Repair (Amst); 2010 Jul; 9(7):745-53. PubMed ID: 20418188
[TBL] [Abstract][Full Text] [Related]
18. XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck.
Vaezi A; Wang X; Buch S; Gooding W; Wang L; Seethala RR; Weaver DT; D'Andrea AD; Argiris A; Romkes M; Niedernhofer LJ; Grandis JR
Clin Cancer Res; 2011 Aug; 17(16):5513-22. PubMed ID: 21737503
[TBL] [Abstract][Full Text] [Related]
19. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
[TBL] [Abstract][Full Text] [Related]
20. ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation.
De Castro G; Pasini FS; Siqueira SA; Ferraz AR; Villar RC; Snitcovsky IM; Federico MH
Oncol Rep; 2011 Mar; 25(3):693-9. PubMed ID: 21206986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
